Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Passage Bio closes $110mm Series B round

Executive Summary

Passage Bio (AAV-delivered gene therapies for rare monogenic CNS diseases) closed a $110mm Series B financing round led by life sciences investment firm Access Biotechnology (added a board member), which was joined by returning backers OrbiMed, Frazier Healthcare Partners, Versant Ventures, Lily Asia Ventures, New Leaf Venture Partners, and Vivo Capital, along with new investors Boxer Capital of Tavistock Group, Highline Capital Management, Logos Capital, and Sphera Funds Management. Launched earlier this year with a $115.5mm Series A round, Passage will use the proceeds to support further development of its five pipeline programs in-licensed from UPenn. Clinical trials for its lead candidates in GM1 gangliosidosis and frontotemporal dementia are expected in 1H 2020.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies